These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 24385201

  • 1. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
    Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH.
    Ann Rheum Dis; 2014 May; 73(5):909-12. PubMed ID: 24385201
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 3. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.
    Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P.
    Arthritis Res Ther; 2013 Oct 30; 15(5):R171. PubMed ID: 24286269
    [Abstract] [Full Text] [Related]

  • 4. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis.
    Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ.
    Semin Arthritis Rheum; 2013 Aug 30; 43(1):9-17. PubMed ID: 23290690
    [Abstract] [Full Text] [Related]

  • 5. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
    Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C, R4RA collaborative group.
    Lancet; 2021 Jan 23; 397(10271):305-317. PubMed ID: 33485455
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML, all departments of rheumatology in Denmark.
    Ann Rheum Dis; 2011 Jul 23; 70(7):1216-22. PubMed ID: 21551512
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
    Provan SA, Berg IJ, Hammer HB, Mathiessen A, Kvien TK, Semb AG.
    PLoS One; 2015 Jul 23; 10(6):e0130709. PubMed ID: 26114946
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.
    Health Technol Assess; 2011 Mar 23; 15(14):1-278. PubMed ID: 21439251
    [Abstract] [Full Text] [Related]

  • 10. Generalized estimating equation model to compare drug effects on synovitis of the dominant wrist in severe rheumatoid arthritis between tocilizumab versus adalimumab versus abatacept using high-resolution ultrasound.
    Chen YC, Chiu WC, Su FM, Chen JF.
    Int J Rheum Dis; 2018 Sep 23; 21(9):1695-1700. PubMed ID: 29024421
    [Abstract] [Full Text] [Related]

  • 11. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J, Madej M.
    Pol Merkur Lekarski; 2011 Apr 23; 30(178):289-94. PubMed ID: 21595177
    [Abstract] [Full Text] [Related]

  • 12. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S, Everett CC, Naraghi K, Davies C, Dawkins B, Hulme C, McCabe C, Pavitt S, Emery P, Sharples L, Buch MH.
    Health Technol Assess; 2018 Jun 23; 22(34):1-280. PubMed ID: 29900829
    [Abstract] [Full Text] [Related]

  • 13. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
    Favalli EG, Biggioggero M, Marchesoni A, Meroni PL.
    Rheumatology (Oxford); 2014 Sep 23; 53(9):1664-8. PubMed ID: 24729445
    [Abstract] [Full Text] [Related]

  • 14. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
    Furfaro N.
    J Infus Nurs; 2011 Sep 23; 34(2):107-15. PubMed ID: 21399456
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Int J Rheum Dis; 2016 Nov 23; 19(11):1103-1111. PubMed ID: 26692536
    [Abstract] [Full Text] [Related]

  • 16. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
    Wollenhaupt J, Krüger K.
    Z Rheumatol; 2010 Sep 23; 69(7):618-25. PubMed ID: 20703488
    [Abstract] [Full Text] [Related]

  • 17. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
    Dörner T, Schulze-Koops H, Burmester GR, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters MA, Tony HP.
    Clin Exp Rheumatol; 2019 Sep 23; 37(6):937-945. PubMed ID: 31025930
    [Abstract] [Full Text] [Related]

  • 18. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
    Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, Fernandez C, Gray JC, Hartley S, Hulme C, Keenan AM, McCabe C, Redmond A, Reynolds C, Scott D, Sharples LD, Pavitt S, Buch MH.
    BMC Musculoskelet Disord; 2014 Dec 23; 15():452. PubMed ID: 25539805
    [Abstract] [Full Text] [Related]

  • 19. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
    Grøn KL, Glintborg B, Nørgaard M, Mehnert F, Østergaard M, Dreyer L, Krogh NS, Hetland ML.
    Rheumatology (Oxford); 2020 Aug 01; 59(8):1949-1956. PubMed ID: 31764977
    [Abstract] [Full Text] [Related]

  • 20. Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.
    Díaz-Torné C, Ortiz de Juana MA, Geli C, Cantó E, Laiz A, Corominas H, Casademont J, de Llobet JM, Juárez C, Díaz-López C, Vidal S.
    Immunology; 2014 Jul 01; 142(3):354-62. PubMed ID: 24219764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.